New drug cocktail aims to stop transplant rejection in blood cancer patients
NCT ID NCT05289167
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of three drugs (cyclophosphamide, bortezomib, and abatacept) can prevent graft-versus-host disease (GvHD) in people receiving a stem cell transplant for blood cancers. About 74 adults will take part. The goal is to reduce severe immune reactions that can damage the body after transplant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAFT-VERSUS-HOST DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Northwell Health
RECRUITINGNew Hyde Park, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can specially trained immune cells flush out hidden HIV?
- Can a simple blood test outsmart deadly fungal infections in blood cancer?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Frailty check may steer safer cancer care for seniors
- Could gratitude exercises aid blood cancer recovery?
- Can a new tracer light up cancer growth?